Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dabigatran

- PMLiVE

Boehringer creates ‘Captain Zantac’

Animated fireman fronts marketing campaign in US for heartburn remedy

National Institute for Health and Care Excellence NICE logo

NICE questions cost of medicines development

Says pharma should determine if R&D spending of £1bn+ per drug is really necessary

Novartis building

NICE backs Novartis’ Jetrea in rare eye condition

Recommends drug be available for NHS use to treat vitreomacular traction

- PMLiVE

Boehringer readies first cancer drug Gilotrif for US launch

Will mark milestone for the pharma company's oncology research efforts

National Institute for Health and Care Excellence NICE logo

NICE turns down Afinitor for breast cancer

NHS patients in England and Wales will not have routine access to Novartis’ drug

- PMLiVE

UK market access: The importance of a local value story

Meeting the needs of the health service’s new stakeholders

National Institute for Health and Care Excellence NICE logo

NICE forced to look again at Alimta

Procedural error forces watchdog to reconsider rejection of Lilly's lung cancer

- PMLiVE

Pfizer faces NICE rejection for lung cancer drug

Xalkori not cost-effective use of NHS resources in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE recommends tests to detect lung cancer mutation

Offers guidance on what NHS can use to see what patients have the EGFR gene mutation

- PMLiVE

Boehringer eyes obesity market

Aims to widen metabolism portfolio beyond diabetes

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

Boehringer: clinical trial set-up poses challenge in rare diseases

Says more support needed in regulatory process for orphan drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links